# US 2026/0258025 A1 · Inhibitors of tdp-43 and tau aggregation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0258025 A1
- Document ID: US20260258025A1
- Status: Published application
- Kind: A1
- Application number: 19/163,007
- Filed: 2024-03-08
- Published: 2026-09-03
- Earliest claimed: 2023-03-09
- Assignees: Aquinnah Pharmaceuticals, Inc.
- Applicants: Aquinnah Pharmaceuticals, inc.
- Inventors: Joseph P. Vacca
- Web page: https://patentgrep.com/patent/US20260258025A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

## Claims

### Claim 1

A compound of Formula (I):
or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
E is C3-C7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, and E may be optionally substituted;
E′ is absent, or E′ is C3-C7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, and E′ may be optionally substituted; and
R3x and R4 are each H or an independently selected optional substituent.

### Claim 2 (depends on 1)

The compound of claim 1, wherein E′ is absent.

### Claim 3

A compound of Formula (II):
or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
Z1 is N or CR11;
Z2 is N or CR12;
Z3 is N or CR13;
Z4 is N or CR14;
L1 is absent, or L2 is C1-C6 alkylene, C1-C6 heteroalkylene, —O—, —S—, or —NR′—, wherein the C1-C6 alkylene and C1-C6 heteroalkylene are optionally substituted;
A is H, halo, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, and A may be optionally substituted; or A and R11 are taken together with the atoms to which they are attached to form an optionally substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbocyclic, or heterocyclic ring;
R11, R12, R13, and R14 are each independently H or an optional substituent;
each R′ is H or C1-C6 alkyl; and
each of R3x and R4 is independently H or an independently selected optional substituent,
wherein no more than two of Z1, Z2, Z3 and Z4 are N.

### Claim 4

A compound of Formula (II):
or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
Z1 is N or CR11;
Z2 is N or CR12;
Z3 is N or CR13;
Z4 is N or CR14;
L1 is absent, or L1 is C1-C6 alkylene, C1-C6 heteroalkylene, —O—, —S—, or —NR′—, wherein the C1-C6 alkylene and C1-C6 heteroalkylene are optionally substituted by 1-4 independently substituents selected from ═O (oxo), OH, and halogen;
A is H, halo, C1-C10 alkyl, C1-C10 heteroalkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, C6-C10 aryl, 5-6 membered heteroaryl, C6-C10 carbocyclyl, or -5-10 membered heterocyclic ring, and A is substituted by one R1 group and optionally substituted by 1-4 independently selected R2 groups; or A and R11 are taken together with the atoms to which they are attached to form a C3-C7 cycloalkyl, aryl, 5-6 membered heteroaryl, or 3-7 membered heterocyclic ring, wherein the heteroaryl and heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, and wherein each of the rings is optionally substituted by one R1 group and optionally substituted by 1-4 independently selected R2 groups;
each of R11, R12, R13, and R14 is independently H or R3;
R1 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C9 heteroalkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, —NH2, or -L2-G, wherein the C1-C6 alkyl may be optionally substituted with OH, and wherein the C1-C6 heteroalkyl may be optionally substituted with C2-C6 heteroalkynyl;
L2 is absent, or L2 is C1-C6 alkylene, C1-C6 heteroalkylene, —O—, —S—, or —NR′—, wherein the C1-C6 alkylene and C1-C6 heteroalkylene are optionally substituted by 1-4 substituents independently selected from ═O (oxo), OH, and halogen;
G is C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, aryl, 5-6 membered heteroaryl, 6-10 membered carbocyclyl, or 5-10 membered heterocyclyl, wherein the 3-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 5-10 membered heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, and wherein G may be optionally substituted by 1-4 RA substituents;
each RA is independently selected from the group consisting of C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, ═O (oxo), OH, —NMe2, —NHMe, —NH2, CN, and halo;
each R2 is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, ═O (oxo), —OH, —NMe2, —NHMe, —NH2, and halo;
each R3 is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, cyano, and halo;
R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, cyano, and halo;
each R′ is H or C1-C6 alkyl; and
R3x is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo,
wherein no more than two of Z1, Z2, Z3 and Z4 are N.

### Claim 5 (depends on 3, 4)

The compound of claim 3 or 4, wherein R3x is H or C1-C6 alkyl.

### Claim 6 (depends on 3, 4)

The compound of claim 3 or 4, wherein R3x is H or -Me.

### Claim 7 (depends on 3, 4, 5, 6)

The compound of any one of claims 3 to 6, wherein R4 is H, halo, C1-C6 haloalkoxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, or C1-C6 heteroalkyl.

### Claim 8 (depends on 3, 4, 5, 6, 7)

The compound of any one of claims 3 to 7, wherein R4 is H, —Cl, —Br, —OCF3, -Me, —OMe, -Et, -nPr, -iPr,
—CH2OCH3, —CH═CH2, or —CH2CH═CH2.

### Claim 9 (depends on 3, 4, 5, 6, 7, 8)

The compound of any one of claims 3 to 8, wherein Z1 is CR11, Z2 is CR12, Z3 is CR13 and Z4 is CR14.

### Claim 10 (depends on 3, 4, 5, 6, 7, 8)

The compound of any one of claims 3 to 8, wherein Z1 is N, Z2 is CR12, Z3 is CR13 and Z4 is CR14.

### Claim 11 (depends on 3, 4, 5, 6, 7, 8)

The compound of any one of claims 3 to 8, wherein Z1 is CR11, Z2 is N, Z3 is CR13 and Z4 is CR14.

### Claim 12 (depends on 3, 4, 5, 6, 7, 8)

The compound of any one of claims 3 to 8, wherein Z1 is N, Z2 is CR12, Z3 is N, and Z4 is CR14.

### Claim 13 (depends on 3, 4, 5, 6, 7, 8)

The compound of any one of claims 3 to 8, wherein Z1 is N, Z2 is N, Z3 is CR13, and Z4 is CR14.

### Claim 14 (depends on 3, 4, 5, 6, 7, 8)

The compound of any one of claims 3 to 8, wherein Z1 is CR11, Z2 is N, Z3 is CR13 and Z4 is N.

### Claim 15 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The compound of any one of claims 3 to 14, wherein each of R11, R12, R13, and R14 is independently H or R3, wherein each R3 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, and halo.

### Claim 16 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The compound of any one of claims 3 to 14, wherein each of R11, R12, R13, and R14 is independently H or R3, wherein each R3 is independently selected from the group consisting of -Me, -Et, -nPr, -iPr, —CF3, —OMe, —OCF3, —OH, —F, and —Cl.

### Claim 17 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 3 to 16, wherein L1 is absent.

### Claim 18 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 3 to 16, wherein L1 is C1-C6 alkylene, C1-C6 heteroalkylene, or —O—.

### Claim 19 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 3 to 16, wherein L1 is —CH2—, —OCH2—, —NHCH2—, —N(CH3)CH2—, or —O—.

### Claim 20 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 3 to 19, wherein A is selected from the group consisting of halo, C1-C10 alkyl, and C1-C10 heteroalkyl, wherein the C1-C10 alkyl and C1-C10 heteroalkyl are optionally substituted by ═O (oxo).

### Claim 21 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 3 to 19, wherein A is selected from the group consisting of —F, —Cl, -Me, -Et, -nPr, -iPr,
—NHCH3, —N(CH3)2,

### Claim 22 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 4 to 19, wherein A is selected from the group consisting of C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, C6-C10 aryl, 5-6 membered heteroaryl, C6-C10 carbocyclyl, and 5-10 membered heterocyclic ring, and A is substituted by one R1 group and optionally substituted by 1-4 independently selected R2 groups.

### Claim 23 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 4 to 19, wherein A is selected from the group consisting of C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, C6-C10 aryl, and 5-6 membered heteroaryl, and A is substituted by one R1 group and optionally substituted by 1-4 independently selected R2 groups.

### Claim 24 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 3 to 19, wherein A is selected from the group consisting of

### Claim 25 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 4 to 24, wherein each R2 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, ═O (oxo), —OH, —NMe2, —NHMe, —NH2, and halo.

### Claim 26 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 4 to 24, wherein each R2 is independently selected from the group consisting of -Me, -Et, -nPr, -iPr, —CF3, —OMe, —OCF3, ═O (oxo), —OH, —NMe2, —NHMe, —NH2, F, Cl, and Br.

### Claim 27 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 4 to 24, wherein R1 is H or -L2-G.

### Claim 28 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 4 to 24, wherein R1 is -L2-G.

### Claim 29 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 4 to 28, wherein L2 is absent.

### Claim 30 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 4 to 28, wherein L2 is selected from the group consisting of C1-C6 alkylene, C1-C6 heteroalkylene, and —O—.

### Claim 31 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 4 to 28, wherein L2 is —CH2—.

### Claim 32 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 4 to 31, wherein G is C3-C7 cycloalkyl or 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl has 1-3 ring heteroatoms selected from N, O, and S, and wherein G may be optionally substituted by 1-4 RA substituents.

### Claim 33 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 4 to 31, wherein G is 3-7 membered heterocycloalkyl, wherein G may be optionally substituted by 1-4 RA substituents.

### Claim 34 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 4 to 31, wherein G is selected from the group consisting of

### Claim 35 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The compound of any one of claims 4 to 34, wherein each RA is independently C1-C6 alkyl.

### Claim 36 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound of any one of claims 4 to 35, wherein G is selected from the group consisting of

### Claim 37 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound of any one of claims 3 to 35, wherein A is selected from the group consisting of

### Claim 38 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 3 to 24, wherein A is selected from the group consisting

### Claim 39 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 4 to 19, wherein A and R11 are taken together with the atoms to which they are attached to form a C3-C7 cycloalkyl, aryl, 5-6 membered heteroaryl, or 3-7 membered heterocyclic ring, wherein the 5-6 membered heteroaryl and 3-7 membered heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, each of the rings optionally substituted by one R1 group and optionally substituted by 1-4 independently selected R2 groups.

### Claim 40 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 3 to 19, wherein
is selected from the group consisting of

### Claim 41 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 3 to 19, wherein
is selected from the group consisting of

### Claim 42 (depends on 3, 4)

The compound of claim 3 or 4, wherein the compound is of Formula (IIa):
or stereoisomer and/or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 3, 4)

The compound of claim 3 or 4, wherein the compound is of Formula (IIb):
or stereoisomer and/or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 3, 4)

The compound of claim 3 or 4, wherein the compound is of Formula (IIc):
or stereoisomer and/or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 3, 4)

The compound of claim 3 or 4, wherein the compound is of Formula (IId):
or stereoisomer and/or a pharmaceutically acceptable salt thereof.

### Claim 46

A compound of Formula (III):
or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
X1 is NR1, O, S, SO2, CH2, or CHR1;
X2 is N or CH;
R1 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, —NH2, and -L2-G, wherein the C1-C6 alkyl may be optionally substituted with one or more OH, and wherein the C1-C6 heteroalkyl may be optionally substituted with C2-C6 heteroalkynyl;
L2 is absent, or L2 is selected from the group consisting of C1-C6 alkylene, C1-C6 heteroalkylene, —O—, —S—, and —NR′—, wherein the C1-C6 alkylene and C1-C6 heteroalkylene are optionally substituted by 1-4 substituents independently selected from the group consisting of ═O (oxo), OH, and halogen;
G is selected from the group consisting of C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, aryl, 5-6 membered heteroaryl, 6-10 membered carbocyclyl, and 5-10 membered heterocyclyl, wherein the 3-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 5-10 membered heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, and wherein G may be optionally substituted by 1-4 RA substituents;
each RA is independently selected from the group consisting of C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, CN, and halo;
each R2 is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, —NH2, and halo;
each R3 is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, cyano, and halo;
R3x is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo;
R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C9 heteroalkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, cyano, and halo;
each R′ is H or C1-C6 alkyl;
m is 0 or 1;
n is 0 or 1;
p is 0, 1, 2, 3, or 4; and
g is 0, 1, 2, 3, or 4.

### Claim 47

A compound of Formula (III):
or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
X1 is selected from the group consisting of NR1, O, S, SO2, CH2, and CHR1;
X2 is N or CH;
R1 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, —NH2, and -G;
G is selected from the group consisting of C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, aryl, 5-6 membered heteroaryl, 6-10 membered carbocyclyl, and 5-10 membered heterocyclyl, wherein the 3-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 5-10 membered heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, and wherein G may be optionally substituted by 1-4 RA substituents;
each RA is independently selected from the group consisting of C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, CN, and halo;
each R2 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, and halo;
each R3 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo;
R3x is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo;
R4 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo;
m is 0 or 1;
n is 0 or 1;
p is 0, 1, 2, 3, or 4; and
q is 0, 1, 2, 3, or 4.

### Claim 48 (depends on 47)

The compound of claim 47, wherein the compound is of Formula (IIIa):
or stereoisomer and/or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 46, 47, 48)

The compound of any one of claims 46 to 48, wherein X1 is NR1 and X2 is CH.

### Claim 50 (depends on 46, 47, 48)

The compound of any one of claims 46 to 48, wherein X1 is CH2 or CHR1 and X2 is N.

### Claim 51 (depends on 46, 47, 48)

The compound of any one of claims 46 to 48, wherein X1 is NR1 and X2 is N.

### Claim 52 (depends on 46, 47, 48, 49, 50, 51)

The compound of any one of claims 46 to 51, wherein R1 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, OH, and halo.

### Claim 53 (depends on 46, 47, 48, 49, 50, 51)

The compound of any one of claims 46 to 51, wherein R1 is selected from the group consisting of -Me, -Et, -nPr, -iPr, —OMe, —OCF3, —OH, —Cl, —F,

### Claim 54 (depends on 46, 47, 48, 49, 50, 51, 52, 53)

The compound of any one of claims 46 to 53, wherein R3x is H or -Me.

### Claim 55 (depends on 46, 47, 48, 49, 50, 51, 52, 53)

The compound of any one of claims 46 to 53, wherein R3x is H.

### Claim 56 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The compound of any one of claims 46 to 55, wherein R4 is -Me.

### Claim 57 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound of any one of claims 46 to 56, wherein m is 1 and n is 1.

### Claim 58 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound of any one of claims 46 to 56, wherein m is 0 and n is 1.

### Claim 59 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The compound of any one of claims 46 to 58, wherein p is 0.

### Claim 60 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The compound of any one of claims 46 to 59, wherein q is 0.

### Claim 61 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The compound of any one of claims 46 to 60, wherein the compound is of Formula (IIIb):
or stereoisomer and/or a pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The compound of any one of claims 46 to 60, wherein the compound is of Formula (IIIc):
or stereoisomer and/or a pharmaceutically acceptable salt thereof.

### Claim 63 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The compound of any one of claims 46 to 60, wherein the compound is of Formula (IIId):
or stereoisomer and/or a pharmaceutically acceptable salt thereof

### Claim 64 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The compound of any one of claims 46 to 60, wherein the compound is of Formula (IIIe):
or a pharmaceutically acceptable salt thereof.

### Claim 65

A compound of Formula (IV):
or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
Z1 is N or CR11;
Z2 is N or CR12;
Z3 is N or CR13;
Z4 is N or CH;
R11 is selected from the group consisting of H, —OH, halo, C1-C6 alkyl, C1-C6 heteroalkyl, and C1-C6 haloalkoxy;
R12 is selected from the group consisting of H, —OH, halo, C1-C6 alkyl, C1-C6 heteroalkyl, and C1-C6 haloalkoxy;
R13 is H or halo;
R14 is selected from the group consisting of H, halo, C1-C6 alkylene, C1-C6 heteroalkylene, 5-7 membered aryl, 5-7 membered heteroaryl, and 3-7 membered heterocycloalkyl, wherein the R14 may be optionally substituted with one or more R14a;
R14a is selected from the group consisting of C1-C6 alkyl, C1-C6 heteroalkyl, C3-C7 cycloalkyl, 5-7 membered aryl, 3-7 membered heterocycloalkyl, and —C(O)OR14b, wherein the C1-C6 alkyl or the 3-7 membered heterocycloalkyl may be optionally substituted with one or more R14b;
R14b is selected from the group consisting of —OH, oxo, C1-C6 alkyl, C1-C5 heteroalkyl, C2-C6 alkynyl, and 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl may be optionally substituted with one or more C1-C6 alkyl;
wherein when Z2 is CR12, R12 and R14 may be taken together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, or aryl, wherein the cycloalkyl or the heterocycloalkyl may be optionally substituted with one or more C1-C6 alkyl or C1-C6 heteroalkyl;
R3x is H or C1-C6 alkyl; and
R4 is selected from the group consisting of H, halo, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, and C1-C6 haloalkoxy.

### Claim 66 (depends on 65)

The compound of claim 65, wherein Z1 is CR11, Z2 is CR12, Z3 is CR13, and Z4 is CH.

### Claim 67 (depends on 65)

The compound of claim 65, wherein when Z1 is N, Z2 is CR12, Z3 is CR13, and Z4 is CH.

### Claim 68 (depends on 65)

The compound of claim 65, wherein when Z2 is N, Z1 is CR11, Z3 is CR13, and Z4 is CH.

### Claim 69 (depends on 65)

The compound of claim 65, wherein when Z2 and Z3 are N, Z1 is CR11 and Z4 is CH.

### Claim 70 (depends on 65)

The compound of claim 65, wherein when Z2 and Z4 are N, Z1 is CR11 and Z3 is CR13.

### Claim 71 (depends on 65)

The compound of claim 65, wherein R11 is selected from the group consisting of halo, C1-C6 alkyl, C1-C6 heteroalkyl, and C1-C6 haloalkoxy.

### Claim 72 (depends on 65)

The compound of claim 65, wherein R12 is selected from the group consisting of halo, C1-C6 alkyl, C1-C6 heteroalkyl, and C1-C6 haloalkoxy.

### Claim 73 (depends on 71)

The compound of claim 71, wherein R11 is selected from the group consisting of -Me, -Et, —Cl, —F, —OMe, and —OCF3.

### Claim 74 (depends on 71)

The compound of claim 71, wherein R12 is selected from the group consisting of -Me, -Et, —Cl, —F, —OMe, and —OCF3.

### Claim 75 (depends on 71)

The compound of claim 71, wherein R11 is —OH.

### Claim 76 (depends on 71)

The compound of claim 71, wherein R12 is —OH.

### Claim 77 (depends on 65)

The compound of claim 65, wherein R13 is halo.

### Claim 78 (depends on 77)

The compound of claim 77, wherein R13 is —Cl.

### Claim 79 (depends on 65)

The compound of claim 65, wherein R14 is selected from the group consisting of H, halo, C1-C3 alkylene, C1-C6 heteroalkylene, phenyl, 5 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-C3 alkylene, C1-C6 heteroalkylene, phenyl, 5 membered heteroaryl, and 4-6 membered heterocycloalkyl may be optionally substituted with one or more R14a.

### Claim 80 (depends on 79)

The compound of claim 79, wherein R14 is selected from the group consisting of -Et, —O—, —CH2—, -nPr, -iPr, —Cl, NHCH3, —N(CH3)2,
wherein if R14 contains a substitutable atom, that atom may be optionally substituted with one or more R14a.

### Claim 81 (depends on 80)

The compound of claim 80, wherein R14 is selected from the group consisting of -Et, -nPr, -iPr, —Cl, NHCH3, —N(CH3)2,

### Claim 82 (depends on 79)

The compound of claim 79, wherein R14 is selected from the group consisting of

### Claim 83 (depends on 79, 80)

The compound of claim 79, 80, or 82, wherein R14a is selected from the group consisting of C1-C3 alkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, 6 membered aryl, and 4-6 membered heterocycloalkyl, wherein C1-C6 heteroalkyl, C3-C7 cycloalkyl, and 5-7 membered aryl may be optionally substituted with R14b.

### Claim 84 (depends on 83)

The compound of claim 83, wherein R14a is selected from the group consisting of -Me, -Et, —CH2—, nPr,
wherein if R14a contains a substitutable atom, that atom may be optionally substituted with one or more R14b.

### Claim 85 (depends on 84)

The compound of claim 84, wherein R14a is selected from the group consisting of -Me, -Et, nPr,
wherein if R14a contains a substitutable atom, that atom may be optionally substituted with one or more R14b.

### Claim 85 (depends on 79, 82)

The compound of claim 79, 82, or 83, wherein R14a is selected from the group consisting of —C(O)OR14b,

### Claim 86 (depends on 79, 83)

The compound of claim 79, 83, or 85, wherein R14b is selected from the group consisting of oxo, —OH, -Me, C3-C7 heteroalkyl, C2-C3 alkynyl, and 6 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl may be optionally substituted with one or more C1-C6 alkyl.

### Claim 87 (depends on 86)

The compound of claim 86, wherein R14b is selected from the group consisting of oxo, —OH, -Me,
wherein the
may be optionally substituted with oxo or C1-C6 alkyl.

### Claim 88 (depends on 87)

The compound of claim 87, wherein R14b is selected from the group consisting of oxo, —OH, -Me,
wherein the
may be optionally substituted with -Me.

### Claim 89 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The compound of any one of claims 79-88, wherein when Z2 is CR12, R12 and R14 may be taken together with the atoms to which they are attached to form an aryl, cycloalkyl, or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl may be optionally substituted with one or more C1-C6 alkyl or C1-C6 heteroalkyl.

### Claim 90 (depends on 89)

The compound of claim 89, wherein when Z2 is CR12, R12 and R14 taken together are selected from the group consisting of,

### Claim 91 (depends on 65)

The compound of claim 65, wherein R3x is C1-C6 alkyl.

### Claim 92 (depends on 91)

The compound of claim 91, wherein R3x is -Me.

### Claim 93 (depends on 65)

The compound of claim 65, wherein R4 is selected from the group consisting of halo, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, and C1-C6 haloalkoxy.

### Claim 94 (depends on 93)

The compound of claim 93, wherein R4 is selected from the group consisting of —Cl, —Br, —OCF3, -Me, -Et, —OMe,

### Claim 95

A compound selected from any compound set forth in Table 1, or stereoisomer and/or a pharmaceutically acceptable salt thereof.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 95.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96)

A method of treating a subject with a neurodegenerative disease or disorder, wherein the method comprises administering to a subject in need thereof a pharmaceutically effective amount of a pharmaceutical composition of claim 96 or a compound of any one of claims 1 to 94.

### Claim 98 (depends on 97)

The method of claim 97, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, frontotemporal dementia (FTD), FTLD-U, FTD caused by mutations in the progranulin protein or tau protein (e.g., progranulin-deficient FTLD), frontotemporal dementia with inclusion body myopathy (IBMPFD), frontotemporal dementia with motor neuron disease, amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), Huntington's chorea, prion diseases (e.g., Creutzfeld-Jacob disease, bovine spongiform encephalopathy, Kuru, or scrapie), Lewy Body disease, diffuse Lewy body disease (DLBD), polyglutamine (polyQ)-repeat diseases, trinucleotide repeat diseases, cerebral degenerative diseases, presenile dementia, senile dementia, Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), progressive bulbar palsy (PBP), pseudobulbar palsy, spinal and bulbar muscular atrophy (SBMA), primary lateral sclerosis, Pick's disease, primary progressive aphasia, corticobasal dementia, HIV-associated dementia, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, Down's syndrome, multiple system atrophy, spinal muscular atrophy (SMA, e.g., SMA Type I (e.g., Werdnig-Hoffnann disease) SMA Type II, SMA Type III (e.g., Kugelberg-Welander disease), or congenital SMA with arthrogryposis), progressive spinobulbar muscular atrophy (e.g., Kennedy disease), post-polio syndrome (PPS), spinocerebellar ataxia, pantothenate kinase-associated neurodegeneration (PANK), spinal degenerative disease/motor neuron degenerative diseases, upper motor neuron disorder, lower motor neuron disorder, age-related disorders and dementias, Hallervorden-Spatz syndrome, cerebral infarction, cerebral trauma, chronic traumatic encephalopathy, transient ischemic attack, Lytigo-bodig (amyotrophic lateral sclerosis-parkinsonism dementia), Guam-Parkinsonism dementia, hippocampal sclerosis, corticobasal degeneration, Alexander disease, Apler's disease, Krabbe's disease, neuroborreliosis, neurosyphilis, Sandhoff disease, Tay-Sachs disease, Schilder's disease, Batten disease, Cockayne syndrome, Kearns-Sayre syndrome, Gerstmann-Straussler-Scheinker syndrome and other transmissible spongiform encephalopathies, hereditary spastic paraparesis, Leigh's syndrome, demyelinating diseases, neuronal ceroid lipofuscinoses, epilepsy, tremors, depression, mania, anxiety and anxiety disorders, sleep disorders (e.g., narcolepsy, fatal familial insomnia), acute brain injuries (e.g., stroke, head injury), and autism, or any combination thereof.

### Claim 99 (depends on 97)

The method of claim 97, wherein the neurodegenerative disease is amyotrophic lateral sclerosis (ALS).

### Claim 100 (depends on 97)

The method of claim 97, wherein the neurodegenerative disease is Alzheimer's disease.
